ATE304545T1 - Verfahren zur hemmung von tyrosinphosphatase 1b und/oder t-zellenprotein-tyrosinphosphatase und/oder anderen ptpasen mit einem asp-rest in position 48 - Google Patents
Verfahren zur hemmung von tyrosinphosphatase 1b und/oder t-zellenprotein-tyrosinphosphatase und/oder anderen ptpasen mit einem asp-rest in position 48Info
- Publication number
- ATE304545T1 ATE304545T1 AT02740410T AT02740410T ATE304545T1 AT E304545 T1 ATE304545 T1 AT E304545T1 AT 02740410 T AT02740410 T AT 02740410T AT 02740410 T AT02740410 T AT 02740410T AT E304545 T1 ATE304545 T1 AT E304545T1
- Authority
- AT
- Austria
- Prior art keywords
- tyrosine phosphatase
- ptpases
- protein tyrosine
- cell protein
- inhibiting
- Prior art date
Links
- 108010015832 Non-Receptor Type 2 Protein Tyrosine Phosphatase Proteins 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 3
- 230000002401 inhibitory effect Effects 0.000 title abstract 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 title 1
- 102000002063 Non-Receptor Type 2 Protein Tyrosine Phosphatase Human genes 0.000 title 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 title 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 title 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 title 1
- 239000003112 inhibitor Substances 0.000 abstract 5
- 108010015847 Non-Receptor Type 1 Protein Tyrosine Phosphatase Proteins 0.000 abstract 4
- 102000002727 Protein Tyrosine Phosphatase Human genes 0.000 abstract 4
- 102100033001 Tyrosine-protein phosphatase non-receptor type 1 Human genes 0.000 abstract 4
- 108020000494 protein-tyrosine phosphatase Proteins 0.000 abstract 4
- 102100033141 Tyrosine-protein phosphatase non-receptor type 2 Human genes 0.000 abstract 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 abstract 2
- 235000003704 aspartic acid Nutrition 0.000 abstract 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Pulmonology (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200101022 | 2001-06-29 | ||
| DKPA200200105 | 2002-01-21 | ||
| PCT/DK2002/000425 WO2003002569A1 (en) | 2001-06-29 | 2002-06-25 | Method of inhibiting ptp 1b and/or t-cell ptp and/or other ptpases with an asp residue at position 48 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE304545T1 true ATE304545T1 (de) | 2005-09-15 |
Family
ID=26069043
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02740410T ATE304545T1 (de) | 2001-06-29 | 2002-06-25 | Verfahren zur hemmung von tyrosinphosphatase 1b und/oder t-zellenprotein-tyrosinphosphatase und/oder anderen ptpasen mit einem asp-rest in position 48 |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1404682B1 (de) |
| JP (1) | JP2004535451A (de) |
| AT (1) | ATE304545T1 (de) |
| DE (1) | DE60206174T2 (de) |
| WO (1) | WO2003002569A1 (de) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005002574A1 (en) * | 2003-06-24 | 2005-01-13 | Actelion Pharmaceuticals Ltd | Pyrazolidinedione derivatives and their use as platelet aggregation inhibitors |
| US8410284B2 (en) | 2008-10-22 | 2013-04-02 | Merck Sharp & Dohme Corp | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
| WO2010051206A1 (en) | 2008-10-31 | 2010-05-06 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| JP2013520502A (ja) | 2010-02-25 | 2013-06-06 | メルク・シャープ・エンド・ドーム・コーポレイション | 有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体 |
| CA2826649C (en) | 2011-02-25 | 2016-07-26 | Merck Sharp & Dohme Corp. | Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents |
| US20140045746A1 (en) | 2012-08-02 | 2014-02-13 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| US9416141B2 (en) | 2012-09-28 | 2016-08-16 | University Of Washington Through Its Center For Commercialization | Compounds and methods for preventing, treating and/or protecting against sensory hair cell death |
| JP2016516004A (ja) | 2013-02-22 | 2016-06-02 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | 抗糖尿病二環式化合物 |
| WO2014139388A1 (en) | 2013-03-14 | 2014-09-18 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
| WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| EP3253766B1 (de) | 2015-02-06 | 2019-09-04 | University of Washington | Verbindungen und verfahren zur vorbeugung oder behandlung von sensorischem haarzelltod |
| WO2018106518A1 (en) | 2016-12-06 | 2018-06-14 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
| WO2018118670A1 (en) | 2016-12-20 | 2018-06-28 | Merck Sharp & Dohme Corp. | Antidiabetic spirochroman compounds |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999046267A1 (en) * | 1998-03-12 | 1999-09-16 | Novo Nordisk A/S | Modulators of protein tyrosine phosphatases (ptpases) |
| JP2004500308A (ja) * | 1998-03-12 | 2004-01-08 | ノボ ノルディスク アクティーゼルスカブ | プロテインチロシンホスアターゼのモジュレーター |
-
2002
- 2002-06-25 AT AT02740410T patent/ATE304545T1/de not_active IP Right Cessation
- 2002-06-25 EP EP02740410A patent/EP1404682B1/de not_active Expired - Lifetime
- 2002-06-25 JP JP2003508950A patent/JP2004535451A/ja not_active Withdrawn
- 2002-06-25 DE DE60206174T patent/DE60206174T2/de not_active Expired - Fee Related
- 2002-06-25 WO PCT/DK2002/000425 patent/WO2003002569A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| DE60206174T2 (de) | 2006-06-22 |
| EP1404682B1 (de) | 2005-09-14 |
| DE60206174D1 (de) | 2005-10-20 |
| WO2003002569A1 (en) | 2003-01-09 |
| EP1404682A1 (de) | 2004-04-07 |
| JP2004535451A (ja) | 2004-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MEP90508A (en) | New pharmaceutical composition | |
| DE60206174D1 (de) | Verfahren zur hemmung von tyrosinphosphatase 1b und/oder t-zellenprotein-tyrosinphosphatase und/oder anderen ptpasen mit einem asp-rest in position 48 | |
| ATE232873T1 (de) | Phosphonsaürederivate als ptp-1b-inhibitoren | |
| ATE432074T1 (de) | Sulfhydantoine als phosphatisostere zur verwendung als phosphatasehemmer bei der behandlung von krebs und autoimmunerkrankungen | |
| ATE449186T1 (de) | Zusammensetzungen und verfahren zur selektiven nukleinsäureisolierung | |
| DE60329316D1 (de) | Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer | |
| ATE308880T1 (de) | Verfahren zur erhöhung der biologischen effektivität von zusammensetzungen zur pflanzenbehandlung | |
| EA200400606A1 (ru) | ИНГИБИТОРЫ ФАКТОРА Ха И ДРУГИХ СЕРИНОВЫХ ПРОТЕАЗ, ВОВЛЕЧЁННЫХ В КОАГУЛЯЦИОННЫЙ КАСКАД | |
| NO990855L (no) | Substituerte sykliske amin-metallprotease-inhibitorer | |
| EA200000298A1 (ru) | Агонисты простагландинов и их применение для лечения заболеваний костей | |
| BR0215308A (pt) | Pirrolopirimidinas | |
| BRPI0407993B8 (pt) | compostos inibidores de p38 e composições farmacêuticas compreendendo os mesmos | |
| BRPI0507972A (pt) | composto ,composição farmacêutica , uso de um composto, método para inibição da atividade proteolìtica de uma enzima de clivagem pós prolina e composição farmacêutica embalada | |
| DE69821376D1 (de) | Verfahren zur proteinrückfaltung durch verwendung zwitterionischer wirkstoffe von niedrigem molekulargewicht | |
| DE69725354D1 (de) | Intermediate zur Herstellung von Thrombininhibitoren als Anticoagulantien | |
| PT1163208E (pt) | Inibidores de caspase e as suas utilizacoes | |
| ATE538651T1 (de) | Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit | |
| DE60023923D1 (de) | Modulatoren der protein tyrosin phosphatase (ptpases) | |
| BRPI0416287A (pt) | compostos, processo para a manufatura dos mesmos, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades que são moduladas por inibidores de accß e sua utilização | |
| DE602004011255D1 (de) | Phosphinsäurederivate, inhibitoren von beta-sekretase zur behandlung von alzheimer-krankheit | |
| ATE394124T1 (de) | Verfahren, zusammensetzungen und herstellungsgegenstände zur modulierung des knochenwachstums | |
| PE20011085A1 (es) | Compuestos isoxazolquinolin o imidazolquinolin como inhibidores de la proteina resistente a multifarmacos | |
| ATE311388T1 (de) | Pyrimidotriazine als phosphataseinhibitoren | |
| SE9804313D0 (sv) | New compounds | |
| ATE443044T1 (de) | Tace inhibitoren |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |